Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Nov-Dec;14(6):995-8.
doi: 10.1097/gme.0b013e318148b28b.

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer

Catherine M Bender  1 , Susan M Sereika, Adam M Brufsky, Christopher M Ryan, Victor G Vogel, Priya Rastogi, Susan M Cohen, Frances E Casillo, Sarah L Berga
Affiliations

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer

Catherine M Bender et al. Menopause. 2007 Nov-Dec.

Abstract

Objective: Hormones have been implicated as modulators of cognitive functioning. For instance, results of our previous work in women with breast cancer showed that cognitive impairment was more severe and involved more memory domains in those who received adjuvant tamoxifen therapy compared with women who received chemotherapy alone or no adjuvant therapy. Recently aromatase inhibitors such as anastrozole have been used in lieu of tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor-positive, early-stage breast cancer. Plasma estrogen levels are significantly lower in women who receive anastrozole compared with those who receive tamoxifen. We hypothesized, therefore, that anastrozole would have a more profound effect on cognitive function than tamoxifen, a mixed estrogen agonist/antagonist.

Design: To test this hypothesis we compared cognitive function in women with early-stage breast cancer who received tamoxifen with those who received anastrozole therapy in a cross-sectional study. We evaluated cognitive function, depression, anxiety, and fatigue in 31 postmenopausal women with early-stage breast cancer who were between the ages of 21 and 65 years and treated with tamoxifen or anastrozole for a minimum of 3 months.

Results: The results showed that women who received anastrozole had poorer verbal and visual learning and memory than women who received tamoxifen.

Conclusions: Additional, prospective studies are needed to validate and confirm the changes in cognitive function associated with hormone therapy for breast cancer.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64:165–176. - PubMed
    1. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13:61–66. - PubMed
    1. Bender C, Sereika S, Berga SM, Vogel V, Brufsky AM, Ryan CM. Cognitive impairment associated with adjuvant therapy in women with breast cancer. Psychooncology. 2006;15:422–430. - PubMed
    1. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802–1810. - PubMed
    1. Buzdar AU. The ATAC (Arimidex, Tamoxifen Alone or in Combination) trial: an update. Clin Breast Cancer. 2004;5(Suppl 1):S6–S12. - PubMed

Publication types

MeSH terms